AR121483A1 - Hidrato cristalino de un compuesto inhibidor de jak - Google Patents
Hidrato cristalino de un compuesto inhibidor de jakInfo
- Publication number
- AR121483A1 AR121483A1 ARP210100530A ARP210100530A AR121483A1 AR 121483 A1 AR121483 A1 AR 121483A1 AR P210100530 A ARP210100530 A AR P210100530A AR P210100530 A ARP210100530 A AR P210100530A AR 121483 A1 AR121483 A1 AR 121483A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline hydrate
- inhibitor compound
- jak inhibitor
- hydrate
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporciona aquí un hidrato cristalino del compuesto de fórmula (1). También se proporcionan en el presente documento composiciones farmacéuticas que comprenden dicho hidrato cristalino, métodos de uso de dicho hidrato cristalino para tratar enfermedades respiratorias y procesos útiles para preparar dicho hidrato cristalino.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983931P | 2020-03-02 | 2020-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121483A1 true AR121483A1 (es) | 2022-06-08 |
Family
ID=75143791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100530A AR121483A1 (es) | 2020-03-02 | 2021-03-01 | Hidrato cristalino de un compuesto inhibidor de jak |
Country Status (16)
Country | Link |
---|---|
US (2) | US11702415B2 (es) |
EP (1) | EP4114836A1 (es) |
JP (1) | JP2023516640A (es) |
KR (1) | KR20220149585A (es) |
CN (1) | CN115190878A (es) |
AR (1) | AR121483A1 (es) |
AU (1) | AU2021232100A1 (es) |
BR (1) | BR112022017398A2 (es) |
CA (1) | CA3172338A1 (es) |
CL (1) | CL2022002368A1 (es) |
CO (1) | CO2022012476A2 (es) |
IL (1) | IL295613A (es) |
MX (1) | MX2022010795A (es) |
TW (1) | TW202144343A (es) |
WO (1) | WO2021178991A1 (es) |
ZA (1) | ZA202209617B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210056381A (ko) * | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
WO2023230236A1 (en) | 2022-05-26 | 2023-11-30 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ttk阻害作用を有するインダゾール誘導体 |
EP2414340A1 (en) | 2009-04-03 | 2012-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
PL3001903T3 (pl) | 2009-12-21 | 2018-03-30 | Samumed, Llc | 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
TN2016000503A1 (en) | 2014-05-14 | 2018-04-04 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
CA3037243A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
WO2017077288A1 (en) * | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
US20180258546A1 (en) | 2017-03-09 | 2018-09-13 | Lam Research Corporation | Electroplating apparatus and methods utilizing independent control of impinging electrolyte |
EA037748B1 (ru) | 2017-03-09 | 2021-05-18 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Конденсированные имидазо-пиперидиновые ингибиторы jak |
EP3619208B1 (en) | 2017-05-01 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Crystalline forms of a jak inhibitor compound |
AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
SG11202101751XA (en) | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
KR20210056381A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
TWI808250B (zh) | 2018-09-04 | 2023-07-11 | 美商施萬生物製藥研發 Ip有限責任公司 | 用於製備jak抑制劑之方法及其中間體 |
JP2022506111A (ja) | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Jak阻害剤としての2-アザビシクロヘキサン化合物 |
PE20212069A1 (es) | 2019-02-25 | 2021-10-26 | Henan Medinno Pharmaceutical Tech Co Ltd | Compuesto inhibidor de jak y uso del mismo |
US11406640B2 (en) | 2019-03-05 | 2022-08-09 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
CN112279848A (zh) | 2019-07-25 | 2021-01-29 | 四川海思科制药有限公司 | 一种泛JAKs抑制剂及其用途 |
TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
-
2021
- 2021-02-26 TW TW110106884A patent/TW202144343A/zh unknown
- 2021-03-01 AR ARP210100530A patent/AR121483A1/es unknown
- 2021-03-01 JP JP2022552324A patent/JP2023516640A/ja active Pending
- 2021-03-01 MX MX2022010795A patent/MX2022010795A/es unknown
- 2021-03-01 AU AU2021232100A patent/AU2021232100A1/en active Pending
- 2021-03-01 BR BR112022017398A patent/BR112022017398A2/pt unknown
- 2021-03-01 EP EP21713868.4A patent/EP4114836A1/en active Pending
- 2021-03-01 CN CN202180017759.9A patent/CN115190878A/zh active Pending
- 2021-03-01 KR KR1020227034088A patent/KR20220149585A/ko unknown
- 2021-03-01 US US17/249,375 patent/US11702415B2/en active Active
- 2021-03-01 WO PCT/US2021/070207 patent/WO2021178991A1/en active Application Filing
- 2021-03-01 IL IL295613A patent/IL295613A/en unknown
- 2021-03-01 CA CA3172338A patent/CA3172338A1/en active Pending
-
2022
- 2022-08-29 ZA ZA2022/09617A patent/ZA202209617B/en unknown
- 2022-08-31 CO CONC2022/0012476A patent/CO2022012476A2/es unknown
- 2022-08-31 CL CL2022002368A patent/CL2022002368A1/es unknown
-
2023
- 2023-05-31 US US18/326,732 patent/US20240025897A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2022012476A2 (es) | 2022-09-20 |
JP2023516640A (ja) | 2023-04-20 |
CA3172338A1 (en) | 2021-09-10 |
CL2022002368A1 (es) | 2023-04-21 |
AU2021232100A1 (en) | 2022-10-20 |
US20240025897A1 (en) | 2024-01-25 |
WO2021178991A1 (en) | 2021-09-10 |
US11702415B2 (en) | 2023-07-18 |
US20210269437A1 (en) | 2021-09-02 |
IL295613A (en) | 2022-10-01 |
KR20220149585A (ko) | 2022-11-08 |
ZA202209617B (en) | 2023-04-26 |
MX2022010795A (es) | 2022-11-30 |
EP4114836A1 (en) | 2023-01-11 |
BR112022017398A2 (pt) | 2022-10-18 |
TW202144343A (zh) | 2021-12-01 |
CN115190878A (zh) | 2022-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
AR111495A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
ECSP22077299A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k | |
BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
CL2021001190A1 (es) | Compuestos de azalactam como inhibidores de hpk1 | |
EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
CU23801B7 (es) | Análogos de pirazol | |
BR112023015721A2 (pt) | Derivados tricíclicos úteis como inibidores de parp7 | |
AR124868A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
BR112022001164A2 (pt) | Composto, uso de um composto, método para o tratamento ou profilaxia de doenças, composto para uso e composição farmacêutica | |
AR107164A1 (es) | INHIBIDORES DE QUINASA p38 | |
ECSP23075535A (es) | Compuestos cíclicos y métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |